POWER1 Study
Focal Onset Seizures in adults
Phase 2/3Active
Key Facts
About Praxis Precision Medicines
Praxis Precision Medicines (NASDAQ: PRAX) is a clinical-stage biotech company revolutionizing CNS drug development through genetics-based approaches. The company has built a comprehensive pipeline targeting rare epilepsies and neurological disorders, with multiple Phase 2/3 studies currently ongoing including the RESILIENCE and ENERGY programs. Their precision medicine approach focuses on therapeutic targets identified through human genetics, utilizing translational tools and patient-guided development strategies.
View full company profile